COPD: New Treatments

December 31, 2006

Chronic obstructive pulmonary disease(COPD) is the fourth leadingcause of chronic morbidity and mortalityin the United States.1 Its prevalenceand impact are increasing,and the World Bank/World HealthOrganization has projected that it willrank fifth in 2020 as a global burdenof disease.2,3 The economic and publichealth impact of COPD is staggering,because this chronic conditionrequires long-term care, frequentoffice visits, and use ofemergency department and hospitalservices. Thus, there is a pressingneed to discover new therapies thatcontrol symptoms and prevent diseaseprogression.

Chronic obstructive pulmonary disease(COPD) is the fourth leadingcause of chronic morbidity and mortalityin the United States.1 Its prevalenceand impact are increasing,and the World Bank/World HealthOrganization has projected that it willrank fifth in 2020 as a global burdenof disease.2,3 The economic and publichealth impact of COPD is staggering,because this chronic conditionrequires long-term care, frequentoffice visits, and use ofemergency department and hospitalservices. Thus, there is a pressingneed to discover new therapies thatcontrol symptoms and prevent diseaseprogression.An increased understanding ofthe pathophysiologic mechanisms ofCOPD has helped researchers identifypotential targets for new treatments.These include many chemoattractantsand cytokines that drive the inflammatoryresponses in COPD; the signaltransduction pathways activated duringthese processes; the mediators released,including proteases and oxidants;and the cellular responses thatlead to abnormalities in tissue functions,such as mucociliary clearanceand repair.Increased interest in COPD isalso reflected in the number of importantpulmonary guidelines thathave been published since 1974 atboth local and international levels.4Pharmacologic and nonpharmacologicmeasures are aimed at improvingthe quality of care for patients whohave COPD, with smoking cessationmandatory for all patients to slow theprogression of lung function loss.Our focus here is on the pharmacologicoptions for COPD. We identifythe currently available agents and outlineappropriate treatment strategies.We also highlight new areas of researchthat may help guide managementin the future.CLASSIFICATIONOF COPDIn the Global Initiative for ChronicObstructive Lung Disease (GOLD)guidelines, COPD is defined as a "diseasestate characterized by airflowlimitation that is not fully reversible.The airflow limitation is usually bothprogressive and associated with anabnormal inflammatory response ofthe lungs to noxious particles andgases."5 The guidelines also provide asimple classification of disease severityinto 4 stages (Table 1); this stagingsystem can help guide treatment(Table 2).The major physiologic abnormalityin COPD is expiratory airflow limitation,which is measured best byspirometry. Airflow has, therefore, becomethe international measure bywhich most drugs are considered forthe management of COPD. Althoughseveral recent trials have highlightedother useful end points, such as qualityof life, exacerbation frequency, exerciseperformance, and survival,therapies have been based on objectiveimprovements in expiratory airflow.Current pharmacologic therapyis used mainly to control symptoms; itmay also reduce the frequency andseverity of exacerbations, improvehealth status, and improve exercisetolerance.PHARMACOTHERAPYAn effective COPD managementplan includes 4 components: assessingand monitoring disease, reducing riskfactors, managing stable COPD, andmanaging exacerbations.5 Once COPDhas been diagnosed, the treatmentgoals are:

  • Prevention of disease progression.
  • Symptom relief.
  • Improvement in exercise tolerance

and health status.

  • Prevention and treatment of complicationsand exacerbations.5,6

Bronchodilators.

The hallmarkof COPD is airflow obstruction, whichleads to incomplete expiration. Duringexertion, patients with emphysemamay experience a significant amount ofair trapping, which leads to hyperinflation(dynamic hyperinflation) withauto-peak end-expiratory pressurephenomenon. Hyperinflation attributableto incomplete lung emptying-especiallywith exercise-leads to a furtherincrease in intra-alveolar pressureand decreased inspiratory capacity; itaffects the operation of the inspiratorymuscles and results in dyspnea. Bronchodilators are central toCOPD symptom management.

7-10

These agents improve airflow by decreasingairway smooth muscle tone;as a result, improved emptying of thelungs at rest and during exercise leadsto a reduction in dynamic hyperinflation.11 Generally, bronchodilators aregiven on an as-needed or a regularbasis to relieve persistent or worseningsymptoms or on a regular basis to preventor reduce symptoms.The major side effects are dosedependent.Both oral and inhaled formulationsare available, but the latter ispreferable, because adverse effects areless likely to occur and resolve morequickly after treatment has stopped.Tailor bronchodilator therapy to thespecific patient

(Table 3)

.

Anticholinergics.

Contributing factorsthat lead to bronchial obstructionin COPD include mucus hypersecretionand an increased bronchial muscletone, which is mediated by cholinergicmechanisms. The anticholinergicbronchodilators decrease vagal cholinergictone, which is the main reversiblecomponent of COPD; hence,they are usually the first-line drugs inthe management of COPD.Anticholinergic drugs block muscarinicreceptors on airway smoothmuscle and, possibly, on submucosalgland cells. Autoradiographic mappingand functional studies have shown M1(Hm1), M2 (Hm2), and M3 (Hm3) receptorsin human airways, and thesereceptors appear to have differentphysiologic functions.

12

M1 receptors in parasympatheticganglia facilitate cholinergic neurotransmissionand, thus, enhance cholinergicbronchoconstriction, whereasM3 receptors on airway smooth musclecells and glands mediate bronchoconstrictionand mucus secretion.M2 receptors on cholinergic nerveendings inhibit the release of acetylcholineand act as feedback inhibitoryreceptors (autoreceptors). In humanairways, blockade of M2 receptors resultsin increased acetylcholine release

(Figure 1).

Because ipratropium is a comparativelynonselective muscarinic an-tagonist, it blocks M2 receptors aswell as M1 and M3 receptors, and increasedacetylcholine release mayovercome the blockade of muscarinicreceptors in the muscle. This hasprompted a search for selective muscarinicreceptor antagonists that blockeither just M3 or both M1 and M3receptors.Tiotropium is a novel, potent,long-lasting muscarinic antagonist.Like ipratropium, tiotropium has a positivelycharged quaternary ammoniumstructure that is responsible for its limitedsystemic absorption. Studies withcloned human muscarinic receptorshave shown that tiotropium bindsequally well to M1, M2, and M3 receptors.However, when comparedwith other muscarinic antagonists, itdissociates very slowly from M1 andM3 receptors and more rapidly fromM2 receptors.

13,14

Takahashi and colleagues

15

confirmed the long durationof action of tiotropium in binding studieswith cholinergic neural responsesin both guinea pig and human airwaysin vitro.Maesen and colleagues

16

demonstratedthe dose-dependent bronchodilatoryefficacy and duration ofaction of tiotropium in patients withCOPD.In a well-controlled study, Littnerand associates

17

administered tiotropiuminhalation powder once daily to stablepatients with COPD (mean forcedexpiratory volume in 1 second [FEV1],1.08 L [42% of predicted]) and evaluateddose-response characteristics. Tiotropiumwas shown to be safe and effectivein once-daily doses rangingfrom 4.5 to 36 ?g, and patients had improvedspirometric results comparedwith patients given placebo.In patients with COPD, tiotropiumprovides a dose-related bronchodilatationthat persists for more than 24hours

(Figure 2).

16

Long-term studieson the safety and efficacy of 18 ?g oftiotropium once daily are being conducted.This drug, which has beenfiled with the FDA for approval, is likelyto be a useful addition to COPDtherapy.β

2

-

Agonists.

If the outcome of anticholinergictherapy is not optimal,add an inhaled short-acting β

2

-agonist.These bronchodilators improve lungfunction, reduce symptoms, and protectagainst exercise-induced dyspneain patients who have COPD.

18,19

Theprincipal action of β

2

-agonists is torelax airway smooth muscle via activationof adenylate cyclase in the muscle,which, in turn, increases the concentrationof intracellular cyclic adenosinemonophosphate (AMP).

20

Albuterol, a short-acting β2-agonist,has proved a major advance intherapy in the 30 years it has beenused to treat and prevent the symptomsof COPD. This drug usually isadministered via metered-dose inhaler(MDI), dry-powder inhaler, or nebulizer,but also is available in an oral formulation.Albuterol remains the standardbronchodilator for the treatmentof COPD-related acute bronchospasmand acute exacerbations of chronicbronchitis.The main disadvantage of a firstgenerationβ

2

-adrenergic agonist, suchas albuterol, is short duration of action(2 to 4 hours), which requires thedrug to be administered several timesa day. Other short-acting β

2

-agonists(metaproterenol, pirbuterol, terbutaline)are listed in

Table 3.

The need for long-acting bronchodilatorsin patients who have asthmaand COPD was met with salmeterol

21

and formoterol.

22

Salmeterol hasprolonged, specific binding to a secondaryexocite on the β

2

-adrenergicreceptor, resulting in repeated stimulationof the active site, which leads tolonger efficacy.In an attempt to increase theaffinity of agonists for the β

2

-adrenergicreceptor, formoterol was developed.The exact mechanism by whichformoterol exerts prolonged effects onlung function is unknown but may involveinteraction with the membranelipid bilayer.

23

Both salmeterol and formoterolinduce bronchodilatation. Celik and associates

24

demonstrated that after 10minutes, formoterol induced clinicallyand statistically significant improvementin FEV1 compared with placebo,whereas salmeterol required 20 minutesto induce significant improvement.Both of these long-acting β

2

-agonistshave a 12-hour duration of action andare appropriate for twice-daily use.The long-acting β

2

-agonists haveother effects that may be beneficial.Salmeterol inhibits airway smoothmuscle proliferation and inflammatorymediator release. It also exertsnon-smooth muscle effects, such asstimulation of mucociliary transport,cytoprotection of respiratory mucosa,and attenuation of neutrophil recruitmentand activation.

25

Formoterol hasnot been evaluated for such effects.Treatment with long-acting β

2

-agonistsmay reduce the number and severity ofexacerbations; thus, it may reduce theoverall cost of health care for patientswith COPD. In addition, long-acting β

2

-agonists, which can be used twice daily(in contrast to short-acting β

2

-agoniststhat must be used 4 times per day),may improve patient compliance.

Methylxanthines.

The effects androle of xanthine derivatives in the treatmentof COPD remain controversial.However, if the outcome of therapy isnot optimal, adding 100 to 900 mg oftheophylline per day to the regimen ofipratropium with or without a β

2

-agonistcan be considered.Because methylxanthines arenonspecific inhibitors of all phosphodiesteraseenzyme subsets, they have awide range of toxic effects. Toxicity inxanthine derivatives is dose-relatedbecause the toxic-therapeutic ratiois small. Theophylline is the mostwidely available methylxanthine, andit is metabolized by cytochrome P-450mixed-function oxidases. Clearance oftheophylline decreases with age, anda number of drugs and physiologicvariables affect its metabolism.The phosphodiesterase inhibitorshave been reported to have a widerange of nonbronchodilator actionsthat may help the COPD patient.Mahler

26

showed a reduction inbreathlessness in patients who receivedtheophylline. Kirsten and coworkers

27

found that cessation of theophyllinetherapy resulted in significant(

P

28,29 butwhether this reflects changes in dynamiclung volumes or a primary effecton the muscle is not clear. Resultssuggest that theophylline is effective insome patients with COPD and supportits use for patients who remain symptomaticdespite the use of inhaledbronchodilators.Second-generation inhibitors ofphosphodiesterase 4 (PDE4) havebeen evaluated. The earliest medications,such as rolipram, demonstratedmarked anti-inflammatory and bronchodilatoryeffects in vitro and invivo,

30

but use of these compoundswas limited by GI side effects. NovelPDE4 inhibitors that maintain the antiinflammatoryand bronchodilatory activityof rolipram with fewer side effectsare being sought. Currently, roflumilast,piclamilast, and cilomilast arebeing investigated.

31

Bronchodilator combinationtherapy

. Anticholinergics, β-agonists,and phosphodiesterase inhibitors havedifferent mechanisms of action, andthe relative importance of each ofthese may differ at various airwaysites. Thus, β-agonists may increasecyclic AMP and mutually potentiatethe action of methylxanthines that inhibitcyclic AMP breakdown. Crosstalkbetween muscarinic cholinergicreceptors and β-agonist receptors maypromote synergies between agentsthat act at these sites.Clinical trials have supported thecombined use of bronchodilators.

32

Ipratropium has been given effectivelywith several short-acting bronchodilators,and an MDI combining ipratropiumand albuterol was approved by theFDA for use in 1996. When added tosalmeterol, ipratropium therapy resultsin further bronchodilatation. This potentiationmay last up to 10 hours-well beyond the usual duration of actionof ipratropium. Theophylline alsohas been used effectively in combinationwith ipratropium and with shortandlong-acting β-agonists.

33

Corticosteroids.

In COPD, systemiccorticosteroids are recommendedfor treatment of acute exacerbationsonly, and several studies haveshown benefits in this setting.

34

Extendedtreatment for 8 weeks is notmore beneficial than treatment for 2weeks.Four large studies evaluated thelong-term effects of inhaled corticosteroidson lung function decline.

35-38

The principal outcome measure for allthe studies was longitudinal declinein FEV1. Investigators showed that inhaledcorticosteroids did not slow thedecline in lung function that characterizesCOPD and that regular treatmentwith these drugs is appropriate onlyfor symptomatic patients with documentedspirometric responses or forthose with FEV1 of less than 50% ofpredicted and persistent exacerbationsrequiring treatment with antibiotics ororal corticosteroids.

5,6

However, in the Inhaled Steroidsin Obstructive Lung Disease (ISOLDE)trial, which assessed patients with themost severe disease, a significant reductionin exacerbation frequency wasnoted.

39

This was associated with a reductionin the rate of decline in healthstatus. Reduction of exacerbations withinhaled corticosteroids was confirmedin a prospective study with exacerbationsas the primary outcome.

40

Currentrecommendations, therefore, suggestthat inhaled corticosteroids can beused to help prevent exacerbations, particularlyin patients with severe pulmonaryfunction abnormalities who areat increased risk for exacerbations orsevere exacerbations.

5,6

Inhaled corticosteroids can resultin a modest improvement in airflow inCOPD patients, but these improvementsare considerably smaller thanthose seen with bronchodilators. Nevertheless,if dyspnea persists despitemaximal treatment with bronchodilators,a trial with inhaled corticosteroidsis reasonable

(Table 4)

. This trial mayrequire at least 3 months to discernbenefit. Trials with oral corticosteroidsare no longer recommended.

FUTURE DIRECTIONS

We believe that combining drugswith different mechanisms and durationsof action will occupy a centralrole in future management of COPD.The availability of combination therapyshould help enhance patient complianceand result in cost savings.There is an urgent need to developnew drugs that will offer significantimprovement in airflow and arrestlong-term decline in lung function inpatients with COPD. The developmentof drugs with low bioavailability, longdurations of action, predictable side effects,and targeted pharmacologic effectswill improve symptomatic managementof this disease.Future COPD treatments willlikely be based on mechanisms thatare distinct from those of current therapies.A better understanding of thebasic pathophysiologic processes underlyingthe inflammation and tissueremodeling that are characteristic ofCOPD has created novel therapeuticopportunities.The agents that are being investigatedcan block various aspects ofthe inflammatory response, attenuatethe effect of inflammatory mediators,modulate tissue destruction, andstimulate tissue restoration. Thesedrugs may alter the natural courseof COPD and, potentially, reversephysiologic compromise.

References:

REFERENCES:


1.

National Heart, Lung, and Blood Institute.

Morbidityand Mortality: 2002 Chartbook on Cardiovascular,Lung, and Blood Diseases.

National Institutes ofHealth. Available at: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm. Accessed August 5,2002.

2.

Murray CJ, Lopez AD. Evidence-based healthpolicy-lessons from the Global Burden of DiseaseStudy.

Science.

1996;274:740-743.

3.

Murray CJ, Lopez AD. The Global Burden of Disease:

A Comprehensive Assessment of Mortality andDisability from Diseases, Injuries and Risk Factors in1990 and Projected to 2020.

Cambridge, Mass: HarvardUniversity Press; 1996.

4.

Hackner D, Tu G, Weingarten S, Mohsenifar Z.Guidelines in pulmonary medicine: a 25-year profile.

Chest.

1999;116:1046-1062.

5.

Pauwels RA, Buist AS, Calverley PM, et al. Globalstrategy for the diagnosis, management, and preventionof chronic obstructive pulmonary disease.NHLBI/WHO Global Initiative for Chronic ObstructiveLung Disease (GOLD) Workshop summary.

Am J Respir Crit Care Med.

2001;163:1256-1276.

6.

Executive summary: global strategy for the diagnosis,management and prevention of chronicobstructive pulmonary disease. NHLBI/WHOWorkshop Report. Available at: http://www.goldcopd.com/exec_summary/summary_2001/index.html. Accessed October 10, 2002.

7.

Vathenen A. High-dose inhaled albuterol in severechronic airflow limitation.

Am Rev Respir Dis.

1988;138:850-855.

8.

Gross NJ, Petty TL, Friedman M, et al. Dose responseto ipratropium as a nebulized solution in patientswith chronic obstructive pulmonary disease.

Am Rev Respir Dis.

1989;139:1188-1191.

9.

Chrystyn H, Mulley BA, Peake MD. Dose responserelation to oral theophylline in severe chronicobstructive airways disease.

Br Med J.

1988;297:1506-1510.

10.

Higgins BG, Powell RM, Cooper S, TattersfieldAE. Effect of salbutamol and ipratropiumbromide on airway calibre and bronchial reactivityin asthma and chronic bronchitis.

Eur Respir J.

1991;4:415-420.

11.

Gross NJ, Skorodin MS. Anticholinergic, antimuscarinicbronchodilators.

Am Rev Respir Dis.

1984;129:856-870.

12.

Barnes PJ. Muscarinic receptor subtypes in airways.

Life Sci.

1993;52:521-528.

13.

Barnes PJ. The pharmacological properties oftiotropium.

Chest.

2000;117(suppl 2):63S-66S.

14.

Barnes PJ, Belvisi MG, Mak JC, et al. Tiotropiumbromide (Ba 679 BR), a novel long-acting muscarinicantagonist for the treatment of obstructiveairways disease.

Life Sci.

1995;56:853-859.

15.

Takahashi T, Belvisi MG, Patel H, et al. Effectof Ba 679 BR, a novel long-acting anticholinergicagent, on cholinergic neurotransmission in guineapig and human airways.

Am J Respir Crit Care Med.

1994;150:1640-1645.

16

. Maesen FP, Smeets JJ, Sledsens TJ, et al. Tiotropiumbromide, a new long-acting antimuscarinicbronchodilator: a pharmacodynamic study in patientswith chronic obstructive pulmonary disease(COPD). Dutch Study Group.

Eur Respir J.

1995;8:1506-1513.

17

. Littner MR, Ilowite JS, Tashkin DP, et al. Longactingbronchodilation with once-daily dosing oftiotropium (Spiriva) in stable chronic obstructive pulmonarydisease.

Am J Respir Crit Care Med.

2000;161:1136-1142.

18.

Mahler DA, Donohue JF, Barbee RA, et al.Efficacy of salmeterol xinafoate in the treatment ofCOPD.

Chest.

1999;115:957-965.

19.

Boyd G, Morice AH, Pounsford JC, et al. Anevaluation of salmeterol in the treatment of chronicobstructive pulmonary disease (COPD).

Eur RespirJ.

1997;10:815-821.

20.

Lulich KM, Goldie RG, Paterson JW. Betaadrenoceptorfunction in asthmatic bronchialsmooth muscle.

Gen Pharmacol.

1988;19:307-311.

21.

Ullman A, Svedmyr N. Salmeterol, a new longacting inhaled beta 2 adrenoceptor agonist: comparisonwith salbutamol in adult asthmatic patients.Thorax. 1988;43:674-678.

22.

Hekking PR, Maesen F, Greefhorst A, et al.Long-term efficacy of formoterol compared tosalbutamol. Lung. 1990;168(suppl):S76-S82.

23.

Anderson GP, Linden A, Rabe KF. Why arelong-acting beta-adrenoceptor agonists long-acting?Eur Respir J. 1994;7:569-578.

24

. Celik G, Kayacan O, Beder S, Durmaz G. Formoteroland salmeterol in partially reversible chronicobstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration ofaction. Respiration. 1999;66:434-439.

25.

Johnson M, Rennard S. Alternative mechanismsfor long-acting beta(2)-adrenergic agonists in COPD.Chest. 2001;120:258-270.

26.

Mahler DA. The role of theophylline in thetreatment of dyspnea in COPD. Chest. 1987;92(suppl 1):2S-6S.

27.

Kirsten DK, Wegner RE, Jorres RA, MagnussenH. Effects of theophylline withdrawal in severe chronicobstructive pulmonary disease. Chest. 1993;104:1101-1107.

28.

Sherman MS, Lang DM, Matityahu A, CampbellD. Theophylline improves measurements ofrespiratory muscle efficiency. Chest. 1996;110:1437-1442.

29.

Murciano D, Auclair MH, Pariente R, AubierM. A randomized, controlled trial of theophylline inpatients with severe chronic obstructive pulmonarydisease. N Engl J Med. 1989;320:1521-1525.

30.

Barnette MS, Underwood DC. New phosphodiesteraseinhibitors as therapeutics for the treatmentof chronic lung disease. Curr Opin Pulm Med. 2000;6:164-169.

31.

Bundschuh DS, Eltze M, Barsig J, et al. In vivoefficacy in airway disease models of roflumilast, anovel orally active PDE4 inhibitor. J Pharmacol ExpTher. 2001;297:280-290.

32.

Friedman M. Combined bronchodilator therapyin the management of chronic obstructive pulmonarydisease. Respirology. 1997;2(suppl 1):S19-S23.

33.

ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterolplus theophylline combination therapy inthe treatment of COPD. Chest. 2001;119:1661-1670.

34.

Niewoehner DE, Erbland ML, Deupree RH, etal. Effect of systemic glucocorticoids on exacerbationsof chronic obstructive pulmonary disease.Department of Veterans Affairs Cooperative StudyGroup. N Engl J Med. 1999;340:1941-1947.

35.

Vestbo J, Sorensen T, Lange P, et al. Long-termeffect of inhaled budesonide in mild and moderatechronic obstructive pulmonary disease: a randomisedcontrolled trial. Lancet. 1999;353:1819-1823.

36.

Pauwels RA, Lofdahl CG, Latinen LA, et al.Long-term treatment with inhaled budesonide inpersons with mild chronic obstructive pulmonarydisease who continue smoking. European RespiratorySociety Study on Chronic Obstructive PulmonaryDisease. N Engl J Med. 1999;340:1948-1953.

37.

Burge S. Should inhaled corticosteroids beused in the long term treatment of chronic obstructivepulmonary disease? Drugs. 2001;61:1535-1544.

38.

The Lung Health Study Research Group. Effectof inhaled triamcinolone on the decline in pulmonaryfunction in chronic obstructive pulmonary disease.N Engl J Med. 2000;343:1902-1909.

39.

Burge PS, Calverley PM, Jones PW, et al. Randomised,double blind, placebo controlled study offluticasone propionate in patients with moderate tosevere chronic obstructive pulmonary disease: theISOLDE trial. BMJ. 2000;320:1297-1303.

40.

Paggiaro PL, Dahle R, Bakran I, et al. Multicentrerandomised placebo-controlled trial of inhaledfluticasone propionate in patients with chronic obstructivepulmonary disease. International COPDStudy Group. Lancet. 1998;351:773-780.